ReviewPituitary2020
Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature.
Review in Pituitary, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Effect of antineoplastic drug therapies on carcinoma and aggressive pituitary tumors: a systematic review and meta-analysis.Pituitary · 2025Pooled it
- Clinical Efficacy of Temozolomide and Its Predictors in Aggressive Pituitary Tumors and Pituitary Carcinomas: A Systematic Review and Meta-Analysis.Frontiers in neurology · 2021Pooled it
- Heterogeneity of MGMT expression in corticotroph adenomas and mechanism of acquired temozolomide resistance.The Journal of clinical endocrinology and metabolism · 2026Article
- Real-world insights in the use of temozolomide for aggressive pituitary tumours remind us what we still don't know.Pituitary · 2026Article
- Temozolomide in aggressive and metastatic pituitary tumors: a Brazilian multicenter real-world cohort study.Pituitary · 2026Article
- Aggressive and malignant pituitary tumours: does the sex matter?Pituitary · 2026Review
- Aggressive pituitary tumors and pituitary carcinomas: Definition, management, and overview for clinical practice.Neuro-oncology advances · 2025Article
- Analysis of the Prognostic and Immunological Role of HSPB1 in Pituitary Adenoma: A Potential Target for Therapy.Medicina (Kaunas, Lithuania) · 2023Article
- Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain.Frontiers in endocrinology · 2023Article
- Therapeutic response to pazopanib: case report and literature review on molecular abnormalities of aggressive prolactinomas.Frontiers in endocrinology · 2023Review
- Aggressive corticotroph tumors and carcinomas.Journal of neuroendocrinology · 2022Review
- Aggressive prolactinoma (Review).Experimental and therapeutic medicine · 2022Review
- Editorial: Refractory Pituitary Adenoma-Current Challenges and Emerging Treatments.Frontiers in endocrinology · 2022Article
- Chemotherapy of Capecitabine plus Temozolomide for Refractory Pituitary Adenoma after Tumor Resection and Its Impact on Serum Prolactin, IGF-1, and Growth Hormone.Journal of oncology · 2022Article
- Application of Convolutional Neural Network in the Diagnosis of Cavernous Sinus Invasion in Pituitary Adenoma.Frontiers in oncology · 2022Article
- MicroRNA-146b-5p/EPHA7 axis regulates cell invasion, metastasis, proliferation, and temozolomide-induced chemoresistance via regulation of IRAK4/TRAF6/NF-κB signaling pathway in aggressive pituitary adenoma.Histology and histopathology · 2022Article
- An Update on Silent Corticotroph Adenomas: Diagnosis, Mechanisms, Clinical Features, and Management.Cancers · 2021Review
- Aggressive pituitary tumours and pituitary carcinomas.Nature reviews. Endocrinology · 2021Review
- Long-Term Use of Temozolomide as Safe and Effective Therapy for an Aggressive Corticotroph Adenoma in a Very Old Patient.Journal of the Endocrine Society · 2021Article
- Pituitary adenoma or pituitary neuroendocrine tumor: a narrative review of controversy and perspective.Translational cancer research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAggressive pituitary adenomas (APAs) and pituitary carcinomas (PCs) are challenging for their invasive nature, resistance to treatment and recurrences. Temozolomide (TMZ) is used with benefit and well-tolerated toxicity profile in APAs and PCs. In most studies patients received ≤ 12 cycles but the best length of treatment is debated since other options after discontinuation are scarce and a second course is mainly unsuccessful.
methodsWe report outcomes of 8 patients with APAs and PCs treated with TMZ for more than 12 continuous cycles with a literature review. Data were retrospectively collected from Padua and Milan University Hospitals. TMZ was used as a single agent (150-200 p.o. mg/m2 daily, 5/28 days) for 14 to 45 cycles.
resultsEight patients (7 M), 7 APAs and 1 PC. Previous treatments included neurosurgery and radiotherapy in all cases except two giant masses (ACTH-silent APA and prolactinoma). No patient had progression disease (PD) during long-term treatment nor toxicities. No one had complete response (CR) but four had partial response (PR). Four ACTH+ tumors maintained stable disease (SD) but the secretion pattern improved in all. After drug withdrawal, three had delayed PD (2 after 18 and one after 29 months, all ACTH+); two are still in SD.
conclusionsTMZ may be useful and well-tolerated in APAs and PCs as a long-term therapy. PR appears within the first cycles with no escape throughout the treatment; most patients achieve SD. We suggest extended protocols particularly in responsive ACTH+ PAs and PCs, when further therapies may be unsuccessful.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.